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Background: Overlapping first generation drug eluting stents (DES) have been demon-
strated in preclinical models to show evidence of a persistent inflammatory response,
fibrin deposition and delayed endothelialisation. The SIRTAX (Sirolimus-Eluting Versus
Paclitaxel-Eluting Stents for Coronary Revascularization) Trial (n1012) associated the
implantation of overlapping first generation DES with impaired angiographic and adverse
3-year clinical outcomes, including death or myocardial infarction (MI).
Methods: Patient level data from 5 controlled studies of the RESOLUTE Global Clinical
Program evaluating the RESOLUTE zotarolimus-eluting stent (R-ZES) were pooled
(n5130). Enrolment criteria encompassed more complex patients, including acute MI,
long lesions, unprotected left main, bifurcations, total occlusions, bypass grafts & visible
thrombus. The position of the R-ZES in relation to the previous implanted stents during
the index or staged procedures were reported by the study site as either ‘separate,’
‘abutting’ or ‘overlapping.’ Comparisons of clinical outcomes – using propensity score
adjustment of baseline anatomical and clinical characteristics – were undertaken between
patients implanted with at least one overlapping DES against patients with no overlapping
DES (Kaplan Meier analyses).
Results: 644 of 5130 study patients (12.6%) underwent overlapping DES implantation.
Baseline characteristics indicated that the implantation of overlapping DES compared to
non-overlapping DES (n4486) were performed more frequently in the RCA and in more
complex coronary lesions. Thirty day, 1 & 2 year clinical outcomes indicated comparable
all-cause death (2 year overlap vs. non overlap: 5.1% vs. 3.5%, p0.13), cardiac death
(3.0% vs. 2.1%, p0.36), MACE (13.3% vs. 10.7%, p0.19), target lesion (10.9% vs.
9.0%, p0.41) & target vessel (12.8% vs. 10.6%, p0.25) failure, and stent thrombosis
(ARC definite/probable 1.4% vs. 0.9%, p0.16).
Conclusions: The adverse clinical outcomes associated with 1st generation DES were
not apparent with 2nd generation DES. Overlapping second generation DES (compared
to the non overlap) is safe & effective with comparable 2 year clinical outcomes, including
repeat revascularisation.
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Background: The new drug-eluting stent BioMime™ (Meril Life Sciences Pvt. Ltd.,
Gujarat, India) is composed of an ultra-thin platform (strut thickness 0.0026’’), a
biodegradable polymer and sirolimus. Its clinical efficacy and safety had already been
demonstrated. However, the impact of the BioMime™ SES on populations from daily
practice with complex lesions is not fully determined.
Methods: The meriT-2 was a prospective, non-randomized, multicenter study, with
minimally selected patients and evaluated clinical and safety performance of the
BioMime™ SES in the treatment of complex patients from daily practice. Native
coronary lesions ranging from 2.5-3.5 mm in diameter and with 37 mm in length, and
chronic total occlusions were included. Lesions located at the left main coronary or in
saphenous vein grafts, or patients with acute myocardial infarction (MI) or left ventricular
ejection fraction30% were excluded. Clinical follow-up (FU) was performed in 1, 8 and
12 months; angiographic FU at 8 months. The primary outcomes were major adverse
cardiac events (MACE: death, MI and target-lesion revascularization –TLR) in 1 month,
and late lumen loss (LLL) in 8 months.
Results: A total of 242 patients were included. Mean age was 56.7 years, 37% diabetics,
32% had previous MI, most with type B2/C lesions, 40% with multiarterial disease and
52% presenting in acute coronary syndrome. Medians of lesion length, reference diameter
and % stentosis were: 15.8mm [13.47-21.42], 2.79mm [2.42-2.99], and 89.8 [83.2-93.2],
respectively. A total of 363 stents were implanted. There were no MACE afer 30 days and
the LLL in 8 months (n132) was 0.15 mm [0.09-0.33]. Cumulative rates of MACE in
12 months were 5.7% (0.5% cardiac death; 4.7% TLR). There were 3 cases of stent
thrombosis (ST) - 1 acute, 1 sub-acute and 1 late.
Conclusions: In this multicenter evaluation of complex “real-world” patients, the new
BioMime™ SES has shown excellent efficacy and safety, with low rates of MACE and
ST in 1 year, as well as low values of LLL.
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Background: Diffuse long lesions are commonly encountered in routine clinical practice
and often lead to use long or overlapping stents. Limited data are available on the
long-term efficacy and safety of long drug-eluting stents (DES) in this complex lesion
subset. We investigated the long-term efficacy and safety of38mm-long DES in patients
undergoing stent implantation for de novo diffuse long lesions.
Methods: 129 consecutive patients who underwent coronary artery stenting with
38mm-long DES in real world practice were included. Study endpoints were major
adverse cardiac events including cardiac death, myocardial infarction, repeat revascular-
ization and stent thrombosis.
Results: 129 pts with 153 lesions were enrolled, 85.2% were male, mean age 58.210
yrs. Lesions were treated with at least one 38mm second generation DES, all post-dilated
at high atmosphere (20 atm) with NC balloons. Mean stent size was 3.00.2 mm, mean
stent length was 54.5 mm. Two-year clinical outcomes were compared between diabetic
(DM) (n40) and non-DM patients (n89). Baseline characteristics were similar in the
two groups as were mean stent length (50.2  13.1 mm in DM and 54.5  15.7 in
non-DM, p  0.12). Mean follow-up duration was 433275 days, and 2-yr cumulative
major adverse cardiac events were significantly lower in the non-DM than in DM group
(5.6% in non-DM vs 10% in DM, p  0.03). Clinically driven TLR was 5.4% and no
cardiac death was reported. There was 1 case defined as late stent thrombosis. The
independent predictors of repeat revascularization were insulin treated type 2 diabetes
mellitus, reference vessel diameter (RVD) 2.75 mm and the use of overlapping DES
longer than 60 mm.
Conclusions: The use of 38mm DES for treatment of complex diffuse disease is safe
and effective with an acceptably low 2-year MACE rate. The need for repeat revascular-
ization was increased with overlapping long DES, small RVD, and insulin treated DM
patients.
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Background: Dissections during stenting are rare but can lead to clinical complications
and necessitate use of a secondary stent thus increasing direct cost of the procedure. This
study examined four popular DES products (Resolute Integrity-Medtronic; Xience Prime
and Xience V-Abbott; and Promus Element-Boston Scientific) using a bench model
developed to explore factors that contribute to dissections.
Methods: Devices (n5) were inserted into mock vessels designed to match the
compliance of a native artery and inflated from nominal to 20-atm pressure. Inner
diameters and outward pressures against the vessel wall were ascertained at 500-m
increments at each inflation pressure. Desired forces within stent body were compared to
undesired forces associated with balloon transition and overhang.
Results: Resolute Integrity and Promus Element exerted consistent pressures within the
device body and decreasing forces in the distal balloon overhang regions. Xience devices
flared as they approached the distal transition, and highest vessel stretch was observed in
the balloon overhang. This flaring or “trumpeting” phenomenon was not observed in other
DES.
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